Study guide
25.2 Cutaneous Malignancy
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
25.2 Cutaneous Malignancy
Key Takeaways Explain This Topic AI
Breslow thickness is the single strongest prognostic factor in cutaneous melanoma and determines excision margins.
Basal cell carcinoma is a slow-growing pearly nodule with rolled edges and telangiectasia that almost never metastasises; squamous cell carcinoma grows faster, may ulcerate and can metastasise.
Immunosuppressed transplant recipients have a greatly increased risk of squamous cell carcinoma and need regular skin surveillance.
Last updated: September 2026
- 4. Cutaneous Malignancies
- Malignant Melanoma
Malignant melanoma originates from cutaneous melanocytes. Incidence is escalating rapidly in the UK, driven by intermittent intense ultraviolet radiation (sunburn) in fair-skinned individuals (Fitzpatrick skin types I–II).
The Clinical ABCDE Criteria:
A — Asymmetry: One half of the lesion does not mirror the other.
B — Border Irregularity: Notched, scalloped, ragged, or poorly defined edges.
C — Colour Variegation: Multiple shades of brown, black, blue, red, or depigmented white.
D — Diameter: >6 mm (diameter of a pencil eraser; though melanomas can present smaller).
E — Evolving: Any change in size, shape, colour, elevation, bleeding, or pruritus ( most sensitive clinical indicator ).
Diagnostic Biopsy: Suspicious pigmented lesions must undergo a complete excisional biopsy with a 2 mm margin of normal skin down to the subcutaneous fat. Incisional, punch, or shave biopsies are strictly contraindicated because they risk inaccurate histological staging.
Breslow Thickness & Wide Local Excision Margins:
Breslow Thickness is the single most important independent prognostic factor for survival and metastatic risk. It measures the vertical microscopic depth in millimetres from the top of the epidermal granular layer to the deepest invasive malignant melanoma cell.
- Breslow Thickness Definitive Wide Local Excision (WLE) Margin Sentinel Lymph Node Biopsy (SLNB) Staging
- Melanoma in situ 5 mm surgical margin Not indicated
Invasive Melanoma <1.0 mm 1 cm surgical margin Not indicated (unless high-risk features: ulceration, mitotic rate ≥1/mm^2)
- Invasive Melanoma 1.0–2.0 mm 1 to 2 cm surgical margin Offer SLNB for nodal staging
- Invasive Melanoma 2.1–4.0 mm 2 cm surgical margin Offer SLNB for nodal staging
- Invasive Melanoma >4.0 mm 2 cm surgical margin Offer SLNB + systemic CT/PET-CT staging
Molecular Genetics & Systemic Therapy:
BRAF V600E Mutation: Present in ~50% of cutaneous melanomas; drives constitutive hyperactivation of the MAPK/ERK pathway. Targeted combination therapy: BRAF inhibitor (dabrafenib, vemurafenib) + MEK inhibitor (trametinib, cobimetinib) .
Immune Checkpoint Inhibitors: First-line systemic therapy for advanced or metastatic melanoma: Anti-PD-1 antibodies (Nivolumab, Pembrolizumab) monotherapy or combined with Anti-CTLA-4 (Ipilimumab) . Candidates must watch for immune-related adverse events (colitis, hypophysitis, hepatitis, thyroiditis, pneumonitis).
- Non-Melanoma Skin Cancers: BCC vs SCC Comparison of Non-Melanoma Skin Cancers
- │
- ├── BASAL CELL CARCINOMA (BCC) — Commonest Human Malignancy
- │ ├── Histogenesis: Basal layer of epidermis and follicular outer root sheath
│ ├── Clinical Phenotype (Nodular BCC ~60%):
- │ │ ├── Pearly, translucent pink/flesh-coloured nodule with arborising telangiectasias
- │ │ └── Rolled, rounded borders with central depression or ulceration ("Rodent Ulcer")
- │ ├── Behaviour: Slow-growing, locally tissue-destructive; metastatic potential negligible (<0.01%)
│ └── Management:
- │ ├── Surgical excision with 4–5 mm margin (curative in >95%)
- │ ├── Mohs Micrographic Surgery (for facial "H-zone", morpheaform, or recurrent lesions)
- │ └── Advanced/Metastatic BCC: Hedgehog pathway inhibitors (Vismodegib, Sonidegib)
- │
- └── SQUAMOUS CELL CARCINOMA (SCC) — Second Most Common Skin Malignancy
- ├── Histogenesis: Malignant proliferation of epidermal keratinocytes; UV-damaged skin
- ├── Precursor Lesions: Actinic keratosis (rough sandpapery macule); Bowen's disease (SCC in situ)
- ├── Clinical Phenotype: Indurated, firm, hyperkeratotic erythematous nodule with central ulcer/crust
- ├── Keratoacanthoma: Rapidly growing dome nodule with central keratin crater (well-differentiated SCC)
├── Immunosuppression Pearl:
- │ └── 65- to 250-fold increased incidence in solid organ transplant recipients (ciclosporin/azathioprine)
- ├── Metastatic Risk Factors: Size >2 cm, depth >4 mm, lip/ear location, perineural invasion, immunosuppression
- └── Management: Surgical excision with 4–6 mm margin (low-risk) or >=6–10 mm / Mohs surgery (high-risk)
- Melanoma in Detail
Melanoma is the skin cancer that kills, and Part 1 questions revolve around recognition, prognosis and the referral pathway rather than surgical technique.
- Subtype Features
- Superficial spreading Commonest (about 70%); trunk in men, legs in women; long radial growth phase
- Nodular Second commonest; rapid vertical growth, often amelanotic; worst prognosis for its size
- Lentigo maligna melanoma Chronically sun-damaged face of older patients; slow evolution from lentigo maligna
Acral lentiginous Palms, soles and nail beds; the commonest subtype in darker skin, and frequently diagnosed late
The ABCDE rule (Asymmetry, Border irregularity, Colour variegation, Diameter above 6 mm, Evolution) and the 7-point checklist used in UK primary care both feed the two-week-wait suspected cancer referral . Subungual melanoma presents as a pigmented longitudinal nail streak, and pigment spreading onto the proximal nail fold — Hutchinson sign — is the malignant clue.
Breslow thickness , measured in millimetres from the granular layer to the deepest tumour cell, is the dominant prognostic factor and sets the wide local excision margin. Sentinel lymph node biopsy is offered for staging in intermediate-thickness disease. Metastatic melanoma is now treated with BRAF and MEK inhibitors where a BRAF V600 mutation is present, or with immune checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab — whose immune-related adverse effects (colitis, hepatitis, hypophysitis, thyroiditis, pneumonitis) are themselves examinable general medicine.
Premalignant Lesions and Non-Melanoma Skin Cancer
Actinic (solar) keratosis : rough, scaly erythematous macules on sun-exposed skin; low individual risk of transformation, treated with cryotherapy, topical fluorouracil, imiquimod or diclofenac gel.
Bowen disease : squamous cell carcinoma in situ, a well-demarcated scaly erythematous plaque, classically on the lower leg of older women.
Keratoacanthoma : rapidly growing crateriform nodule with a keratin plug that may regress spontaneously, but is excised because it cannot be reliably distinguished from squamous cell carcinoma.
Risk Factors and Genodermatoses
Cumulative ultraviolet exposure, Fitzpatrick skin types I-II, immunosuppression, previous radiotherapy, chronic scarring ( Marjolin ulcer ) and arsenic exposure all raise risk. Organ transplant recipients have up to a 100-fold increase in squamous cell carcinoma , which behaves aggressively and warrants annual dermatological surveillance and, where possible, reduction or conversion of immunosuppression. Gorlin syndrome (naevoid basal cell carcinoma syndrome, PTCH1 ) causes multiple early basal cell carcinomas, odontogenic keratocysts and palmar pits, and xeroderma pigmentosum causes early multiple skin cancers through defective nucleotide excision repair.